CPhI And PMEC India 2017 at a glance

11 Dec 2017

• South Asia’s largest Pharma event
• Held at two different venues i.e., MMRDA Grounds (BKC), Mumbai – 27^th to 29^th Nov ;  the Bombay Exhibition Centre (Goregaon) – 28th to 30th Nov
• 1,500 + exhibitors, a 40+ countries’ participation
• Salient features include Supplier-Finder Desk, Innovation Gallery  and Exhibitor Showcase

 
UBM India, India's leading B2B exhibition organizer saw the launch of the grand 11th edition of the signature event, CPhI & P-MEC India 2017, one of the world’s leading pharma networking expos.  The marquee expo is being held at two venues in Mumbai - MMRDA Grounds, Bandra Kurla Complex (27^th to 29^th November) and Bombay Exhibition Centre (28th to 30^th November).
 
This year's marquee event has more than 1,500 + exhibitors, 40 + countries’ participation. The inauguration of CPhI-P-MEC 2017 occurred at MMRDA Grounds, Bandra Kurla Complex today in the presence of an august gathering of industry leaders including Shri. Satish Wagh, Chairman, Chemexcil, Mr. Rahul Deshpande, Group Director, UBM India, Mr. Jime Essink, Chief Executive Officer, UBM Asia Ltd, Mr. Aasif Khan, Director, Fabtech Technologies, Mr. Rajendra Khimsaria, Director, Khimsaria Associates, Mr. Khaja Nizamuddin, Director, Pharmapack Packaging  Equipment, Mr. Yogesh Mudras, Managing Director, UBM India  and other key dignitaries
 
Alongside the expo, UBM India launched the second edition of the India Pharma Week (IPW), an attractive platter of more than ten trend-setting events that got off to a flying start on November 25. Focusing on the pillars of business, knowledge, leadership, innovation, recognition and networking in the pharma domain, the IPW includes a Plant Visit, Pharma Leaders’ Golf, Pre-Connect Congress, Women in Pharma – Power Breakfast, the India Pharma Awards, Networking Evening, a closed door CEO Roundtable and many more activities. The IPW has transformed the CPhI & P-MEC exhibition from a wall-bound show to one with considerable intellectual value addition.
 
Originating from CPhI Worldwide, the CPhI & P-MEC India was first introduced in 2006. Today, it has become South Asia's leading pharma meeting place, covering every step of the supply chain, from drug discovery to finished dosage. CPhI India is an industry platform encompassing CROs, CMOs and manufacturers of API, Generics, Excipients and Drug formulation, Fine chemicals, Biosimilars, Finished Formulations, Lab chemicals and Biotechnology. P-MEC, on the other hand, includes manufacturers of Pharma Machinery and Equipment, Analytical Equipment, Automation & Robotics, Packaging Equipment & Supplies, Plant/Facility Equipment, Automation & Controls, Processing Equipment, RFID, Tableting / Capsule fillers, Clean room equipment, Filling equipment and Laboratory products.
 
The show has grown exponentially over the years, with domestic and foreign exhibitors and visitors engaging over significant levels of business. This year, the expo comprised exciting facets such as the Supplier-Finder Desk (a digital floor plan that enabled visitors find exhibitors based on services or company names), Innovation Gallery (an arena where participating pharma companies were encouraged to showcase innovations on an international platform) and Exhibitor Showcase (a platform where exhibitors demonstrated how their new product launches are going to be efficacious.)
 
The key companies exhibiting in the 2017 edition at CPhI include Aurobindo Pharma Ltd., Granules India Pvt. Ltd., Hetero Labs Limited, Signet Chemical Corporation Pvt. Ltd, DKSH India Pvt. Ltd., Morepen Laboratories Limited, N V Organics Pvt. Ltd. amongst others. On the other hand, some of the leading companies such as West Pharmaceuticals Packaging India Pvt. Ltd., Cadmach Machinery Co. Pvt.  Ltd., Brothers Pharmamach (I) Pvt. Ltd, NPM Machinery Pvt. Ltd., Jekson Vision Pvt. Ltd., ACG Worldwide Solid Dosage Consumables and Machinery, Ace Technologies & Packaging Systems Pvt. Ltd, Fabtech Technologies International Ltd., Jagson Engineers, Bosch Limited, Agilent, Food & Pharma Specialities amongst others will exhibit at P-MEC.
 
Renowned as the pharmacy of the world, the Indian pharma economy has been lauded for its rapid growth in recent decades. This has cooled down in recent years, but the industry is again growing strongly. Compounded annual growth is 17.6%; Indian pharma is expected to be worth 55 billion USD by 2020. In line with this, the life science sector in India is also expected to employ close to 3.5 million people by 2022, a 100% increase in under a decade. The Indian pharma industry owes its success to its bold, ambitious approach, history of innovative and an ability to constantly adapt to the dynamic global market.
 
Over the past five years, India has become the leading API and finished dose drug exporter to the Western markets and has rapidly moved up the pharmaceutical value chain. Drug approvals given by the US Food and Drug Administration (USFDA) to Indian companies have nearly doubled from 109 (2014-2015) to 201 (2015-2016), stimulating further growth in exports to the United States and Western economies. Additionally, the Indian government is now providing more support working hand-in-hand with its businesses to develop incentives to further boost growth.
   
Speaking at the inauguration of CPhI & P-MEC India 2017, Mr. Yogesh Mudras, Managing Director, UBM India said,

“India is among the fastest-growing pharmaceutical markets in the world and has established itself as a global manufacturing and research hub. A large raw material base and the availability of a skilled workforce give the industry a definite competitive advantage over other countries. A platform like CPhI & P-MEC India provides a most comprehensive industry platform for every company that deals with pharmaceuticals in India. This year too, we have the expo held at two venues, commencing at BKC today. CPhI and P-MEC India is widely used as a barometer of Pharma’s overall health in India. Being the only platform that brings together Indian and global companies, the mammoth expo is a strong event reflecting and enhancing the value of the prosperous pharma industry.”